CALML3-AS1 recruits EZH2 to inhibit BTNL9 expression, where high BTNL9 expression suppresses NSCLC cell proliferation and migration, potentially through the induction of apoptosis (129). Here, BTNL9 is linked to non-small cell lung carcinoma.